3 edition of Monoclonal antibody therapy of hematologic malignancies found in the catalog.
Monoclonal antibody therapy of hematologic malignancies
Includes bibliographical references and index.
|Statement||edited by Bruce D. Cheson.|
|Series||New frontiers in cancer therapy|
|Contributions||Cheson, Bruce D., 1946-|
|The Physical Object|
|Pagination||x, 287 p. :|
|Number of Pages||287|
New Frontiers in Cancer Therapy: Monoclonal Antibody Therapy of Hematologic Malignancies Article in International Journal of Hematology 75(5) June with 3 Reads How we Author: Akifumi Takaori-Kondo. Antibody-drug conjugates (ADCs) are agents composed of a monoclonal antibody linked to cytotoxic molecules. By specifically delivering cytotoxic agents to cells expressing surface antigens of interest, Cited by: 6.
Introduction: The introduction of monoclonal antibodies (moAbs) into clinical practice revolutionized the treatment strategies in several solid agents differ from cytotoxic chemotherapy for their Cited by: 2. Monoclonal antibodies, either alone or as immuno-conjugates, are now being utilized to treat patients with a wide range of hematologic malignancies. The aim of early studies was to delineate the feasibility of this form of therapy Cited by: 8.
The approval of monoclonal antibodies (MAbs) as antibody-targeted therapy in the management of patients with hematologic malignancies has led to new treatment options for this group of patients. The ability to target antibodies Cited by: Chapter 1. Overview of Hematologic Malignancies. MiKaela Olsen, MS, RN, AOCNS ® Introduction. In , Thomas Hodgkin described the first hematologic malignancy. More than 30 years. later, the .
Model business letters
short history of the interpretation of the Bible.
State of the art of the application of new information technologies in libraries and their impact on library functions in Denmark
Manual of fish culture
catalogue of the works of Linnaeus (and publications more immediately relating thereto) preserved in the Libraries of the British Museum (Bloomsbury) and the British Museum (Natural History) South Kensington
Construction aggregates--crushed stone, sand, gravel, and slag.
España desde el aire
empirical comparison of alternative forecasting methods as applied to the UK foreign holiday market,1973-1976.
The “blockbuster” antibody rituximab is the first-in-class anti-CD20 mAb approved for the treatment of B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL); it is by far the Cited by: This review summarizes the monoclonal antibodies either approved by the FDA or in development for the treatment of hematologic malignancies.
Rituximab, which targets the CD20 antigen, has revolutionized the treatment Author: Kenneth A. Foon, Michael Boyiadzis, Samuel A. Jacobs. Monoclonal Antibodies Targeting Hematological Malignancies. Authors; we summarize the safety and clinical application of therapeutic monoclonal antibodies in the treatment of paediatric haematological malignancies and discuss the future direction of this new targeted therapy Author: Matthew J.
Barth, Jessica Hochberg, Nader Kim El-Mallawany, Mitchell S. Cairo. Request PDF | Monoclonal Antibody Therapy for Hematologic Malignancies | Monoclonal antibodies are a new class of agents that target tumor-associated antigens.
Advances in hybridoma. New Frontiers in Cancer Therapy: Monoclonal Antibody Therapy of Hematologic Malignancies, edited by Bruce D. Cheson. Oxfordshire, United Kingdom: Darwin Scientific Publishing, ; Author: Akifumi Takaori-Kondo.
Over the past decade the potential for delivering targeted therapy against malignant disease by the use of monoclonal antibodies (MAbs) has begun to be realised. Haematological malignancies, because of the relative accessibility of the malignant cell in blood and bone marrow and the understanding of haemopoietic lineage-specific antigens, have provided a successful testing ground for this by: Abstract Apart from radio- and chemotherapy, monoclonal antibodies (MoAbs) represent a new, more selective tool in the treatment of hematological malignancies.
MoAbs bind with the specific antigens of the tumors. This interaction is a basis for targeted therapies which exhibit few side effects and significant antitumor Cited by: 4.
Apolizumab (Hu1D10), a humanized monoclonal anti-human leukocyte antigen- (HLA-) DR betachain antibody, is currently studied in clinical trials for hematologic malignancies. The HLA-DR antigen.
Bispecific Antibodies in the Treatment of Hematologic Malignancies Johannes Duell1, Philip E. Lammers2, Ivana Djuretic3, Allison G. Chunyk4, Shilpa Alekar4, Ira Jacobs5,* and Saar Gill6 Cited by: 3. Apart from radio- and chemotherapy, monoclonal antibodies (MoAbs) represent a new, more selective tool in the treatment of hematological malignancies.
MoAbs bind with the specific antigens of the tumors. This interaction is a basis for targeted therapies which exhibit few side effects and significant antitumor Cited by: 4. Monoclonal antibodies (mAb) are widely used in the differential diagnosis of cancer and are key elements in the treatment of many forms of cancer, particularly hematologic malignancies.
Treatments with mAbs have improved outcome and reduced toxicity compared to more conventional chemotherapy by: 8. Monoclonal antibodies (BITE, ADC) Monoclonal antibodies (mAb) are one of the most commonly used immunotherapies for cancer. Rituximab, the first mAb approved by the FDA inis an anti-CD20 antibody designed to treat B-cell malignancies.
It is a type I antibody that exhibits complement-dependent and antibody-dependent Cited by: 2. Background: The approval of monoclonal antibodies (MAbs) as antibody-targeted therapy in the management of patients with hematologic malignancies has led to new treatment options for this group of patients.
The ability to target antibodies. Objective Patients with resolved hepatitis B virus (HBV) infection are at risk of HBV reactivation during treatment for hematological malignancies. We conducted a systematic review and meta‐analysi Author: Carmen Ka Man Cheung, Man Fai Law, David Chun Chao, Sunny Hei Wong, Rita Ho, Amelia Chien Wei Chao.
Research article Full text access Monoclonal Antibodies for the Treatment of Hematologic Malignancies: Schedule and Maintenance Therapy. Monoclonal Antibody Therapy for Hematologic Malignancies: Prospects for an Integrated Therapy Approach.
select article Introduction—Monoclonal antibody therapy for hematologic malignancies: Prospects for an integrated therapy approach select article Investigation of monoclonal antibody therapy with conventional and high-dose treatment.
Background: Biological agents are proving to be increasingly useful and exciting additions to the antineoplastic armamentarium, but many clinicians are unfamiliar with the properties of these types of agents. Objectives: This review focuses on monoclonal antibodies (MAbs) that are used in the treatment of hematologic malignancies Cited by: Monoclonal antibodies can cause side effects, which can differ from person to person.
The ones you may have and how they make you feel will depend on many factors, such as how healthy you are before treatment, your type of cancer, how advanced it is, the type of monoclonal antibody.
Treatment with monoclonal antibodies of the human IgG1 and IgG2 isotypes have become a mainstay in cancer therapy, particularly, in hematological malignancies (Ball and Broome ).
Several monoclonal antibodies are now approved for cancer therapy, such as rituximab, an anti-CD20 monoclonal antibody for the treatment of B-cell non-Hodgkin's lymphoma.
Request PDF | On Aug 1,John C. Byrd and others published Monoclonal antibody therapy for hematologic malignancies: Introduction | Find, read and cite all the research you need on .Title: Monoclonal Antibodies in the Treatment of Hematologic Malignancies: Radiation Dosimetry Aspects VOLUME: 2 ISSUE: 4 Author(s): M.G.
Stabin and A.B. Brill Affiliation:Department of Cited by: 1.Bispecific Antibodies in the Treatment of Hematologic Malignancies. Monoclonal antibody therapies are an important approach for the treatment of hematologic malignancies, but typically show low single‐agent activity.
Bispecific antibodies Cited by: 3.